🇺🇸 FDA
Pipeline program

[225Ac]Ac-AKY-1189 (therapeutic)

AKY-1189-01

Phase 1 small_molecule active

Quick answer

[225Ac]Ac-AKY-1189 (therapeutic) for Urothelial Carcinoma Bladder is a Phase 1 program (small_molecule) at Aktis Oncology with 1 ClinicalTrials.gov record(s).

Program details

Company
Aktis Oncology
Indication
Urothelial Carcinoma Bladder
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials